DS Biopharma Limited v Controller of Patents and Designs (2022)
High Court of Delhi·Prathiba M. Singh J·Single Judge·Decided 30 August 2022·2022/DHC/003563
A hearing notice raising Section 3(d) must identify the known substance and how the claimed compounds are new forms; refusal set aside, fresh hearing directed.
DS Biopharma Limited v Controller of Patents and Designs, Ali on Patents, www.aop.onl/ds-biopharma
Summary
“The present appeal has been filed on behalf of the Appellant - DS Biopharma Limited, under Section 117A of the Patents Act, 1970”, “challenging the order dated 13th January, 2021 passed by the ld. Assistant Controller of Patents & Designs” (para 2). “The Appellant is a company based in Ireland. It filed Indian Patent Application No.201717040270 on 10th November, 2017” (para 3). “The FER was issued on 5th March, 2020 by the Patent Office, New Delhi”, objecting to “lack of inventive step qua all claims 1-26”, “non-patentability under Section 3(i)” and “lack of clarity and conciseness under Section 10(5) and Section 10(4)(c) of the Act” (para 5). After the Appellant “cancelled claims 7-26”, “a hearing notice was issued on 25th November, 2020, in which the objection was restricted” to “Subject matter claimed in claim 1,4 is not Patentable u/s/ 3 (d) of Patents Act;” (para 6), and “the ld. Assistant Controller of Patents rejected the said patent application vide the impugned order dated 13th January, 2021” (para 8).
The Bench held that “Section 3(d) bars patentability of a ’new form’ of ‘a known substance’, without establishing enhanced therapeutic efficacy” and that “For the said objection to be raised, the basic pre-condition would be the identification of the ‘a known substance’”, which “cannot be left to the Applicant to deduce as to what is the known substance and thereafter give efficacy data qua that known substance” (para 14). Finding that “the compound which constitutes the ‘known substance’ was not identified in the hearing notice” (para 14) and that “The Ld. Controller in the hearing notice has failed to identify any of the above three factors” (para 16), it held that “Therefore, holistically read, the Appellant has not had adequate opportunity to deal with the objection under Section 3(d)” (para 19) and that “In the absence of the proper identification of the known substance in the hearing notice and a lack of proper opportunity being afforded to respond to the objection under Section 3(d), the impugned order is not sustainable” (para 20). “The appeal is allowed in the above terms. The impugned order is set aside.” (para 24)
What the court decided
- Procedure. The description of the claims. The Bench held that “Even if the Court ignores the wrong description of the claims by the Patent Office, clearly, the substantive objection was raised under Section 3(d) of the Act.” (para 13)
- The Fresenius Kabi observations. Recording that “The legal position in respect of an objection under Section 3(d) was considered by the IPAB in ORA/22/2011/PT/KOL titled Fresenius Kabi Oncology Limited v. Glaxo Group Limited & Anr., 2013 SCC OnLine IPAB”, where the Board had held that “It is true that it is the patentee who must prove the enhanced therapeutic efficacy of his invention. But in a revocation the applicant must plead and prove that it is hit by S.3(d) and that it has the same therapeutic efficacy as the known substance.” and that “It is only when the pleadings show how the invention is one kind of a derivative of known substance the patentee will have to explain how the grant of patent is justified because of the enhancement of therapeutic efficacy.” (para 13), the Bench held that “Though not in the context of a patent office objection, the observations would be relevant to examine as to how the objection under Section 3(d) is to be raised.” (paras 13–14)
- Identification of the known substance. “Section 3(d) bars patentability of a ’new form’ of ‘a known substance’, without establishing enhanced therapeutic efficacy. For the said objection to be raised, the basic pre-condition would be the identification of the ‘a known substance’. The said ‘known substance’ could be one substance or a compound/s derived from a Markush formula. However, it has to be identified. It cannot be left to the Applicant to deduce as to what is the known substance and thereafter give efficacy data qua that known substance, based on the said deduction. It is only new forms of substances which are derived from the same known substance that would attract the rigors of Section 3(d).” (para 14)
- What the hearing notice must state. “However, in this case, the compound which constitutes the ‘known substance’ was not identified in the hearing notice. For the purposes of a Section 3(d) objection, the one specific known substance is to be identified and the manner in which the claimed compounds are ’new forms’ ought to be mentioned by the Patent Office, even if not in detail but at least in a brief manner. The hearing notice does not mention so.” (para 14)
- The three factors. The Appellant had asserted that “the patent office needs to specifically allege and identify at least the following:” “(i) What is the specific ‘known’ substance in question? ... (iii) Basis to assert that the alleged ‘known’ substance and the claimed molecule or substance have the same ‘known’ efficacy?” (para 15), and the Bench held that “The Ld. Controller in the hearing notice has failed to identify any of the above three factors.” (paras 15–16)
- The known substances identified. “Thus, the Controller clearly holds in the impugned order that the identified compounds are in D1 and D4 in which at position 15, a substitution has been made by the Appellant. The identified known substances are also in D6 where the presence of double bond between C17 and C18 of the carboxylic acid chain, instead of the single bond in the claim of the Appellant. These facts could have been contained in the hearing notice, upon which, the Appellant could have responded as to how the objection under Section 3(d) was not attracted. The Appellant could have also established that the subject compounds had enhanced therapeutic efficacy to satisfy the pre-conditions under Section 3(d).” (para 18)
- Adequate opportunity. “Therefore, holistically read, the Appellant has not had adequate opportunity to deal with the objection under Section 3(d) in as much as apart from merely specifying the said objection for the first time in the hearing notice, the manner in which the said objection was attracted was completely absent.” (para 19) “In the absence of the proper identification of the known substance in the hearing notice and a lack of proper opportunity being afforded to respond to the objection under Section 3(d), the impugned order is not sustainable.” (paras 19–20)
- The corresponding foreign grant. On the submission “that the corresponding patent application in the U.S.A. has been granted in favour of the Appellant and is pending in other jurisdictions”, the Bench held: “Be that as it may, Section 3(d) is unique to the Patents Act, 1970 in India. The Appellant would have to deal with this objection which has now been clearly crystallized in the impugned order and has also been captured above.” (para 21)
- Clarity and conciseness. “Insofar as clarity and conciseness in concerned, having perused the final four claims, this Court is of the opinion that the objection under Section 10(4)(c) and Section 10(5) of the Act would not arise in the present appeal.” (para 23)
- Directions and disposition. “In order to afford the Appellant a fair opportunity to deal with this objection, the following directions are issued:” “The Appellant shall file its response on the basis of the identified known substances and the extracts of the impugned order as set out above. In response, the Appellant may also produce efficacy data and support its submissions as to how Section 3(d) is not applicable.” “The said response shall be filed by the Appellant within a period of 8 weeks - upon which, a fresh hearing shall be granted on the issue of whether the claims 1-4 are liable to be granted or not in view of the objections under Section 3(d) of the Act.” “The Controller is also permitted to consider along with the objection of Section 3(d) the objection relating to lack of inventive step, if any.” (para 22) “The Controller shall make endeavour to decide the appeal within a period of six months from today.” (para 23) “The appeal is allowed in the above terms. The impugned order is set aside.” (paras 22–24)
What the court did not decide
“Nothing stated in the impugned order or in the present order would bind the Controller on the merits of the objections which are to be dealt with him under Section 3(d) or under Section 2(1)(ja) of the Act.” (para 24)
Subsequent treatment
- Followed — In Taiho Pharmaceutical Co Ltd v Controller of Patents (2025) the Delhi High Court held that “The ratio of DS Biopharma (supra) is fully applicable in the facts and circumstances of the present case.” (para 15)
Provisions and topics
Cited in
New Forms of a Known Substance
Enhanced Therapeutic Efficacy
Appeals from the Controller
Case page · Page updated 9 November 2026
www.aop.onl/ds-biopharma